Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-20T02:30:49.937Z Has data issue: false hasContentIssue false
  • English
  • Français

Atypical neuroleptics: their contribution to the rehabilitation of schizophrenic patients

Published online by Cambridge University Press:  16 April 2020

JM Vanelle ,
T Brochier ,
FJ Baylé  and
H Lôo
JM Vanelle
Affiliation:
Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Centre Hospitalier Spécialisé Sainte-Anne, 1 rue Cabanis, 75674Paris cedex, France
T Brochier
Affiliation:
Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Centre Hospitalier Spécialisé Sainte-Anne, 1 rue Cabanis, 75674Paris cedex, France
FJ Baylé
Affiliation:
Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Centre Hospitalier Spécialisé Sainte-Anne, 1 rue Cabanis, 75674Paris cedex, France
H Lôo
Affiliation:
Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Centre Hospitalier Spécialisé Sainte-Anne, 1 rue Cabanis, 75674Paris cedex, France
Get access

Summary

Therapeutic effects of neuroleptics (NLP) in schizophrenia are well established in numerous international studies. Varying modalities of evolution under NLP treatment are described and require a clinical analysis. Neuroleptics are a necessary but insufficient condition for the therapy of schizophrenia. Via NLP treatment, other therapeutic approaches, such as psychotherapy, or sociotherapy become more effective. Consecutively, we present the effects of two compounds with dopaminergic selective activity (amisulpride, remoxipride) and of two other compounds with non-selective activity (risperidone, clozapine) regarding rehabilitation in schizophrenic patients. Data were collected from international studies with a medico-economic perspective and from French experience of clozapine in refractory schizophrenic patients. All these data stress the importance of several areas of study: clinical features, everyday life consequences and therapeutical effects observed with the atypical neuroleptics.

Keywords

schizophreniaatypical neurolepticsamisulpriderisperidoneclozapine
Type
Research Article
Information
European Psychiatry , Volume 11 , Issue S2: The rehabilitation of patients with long-term psychiatric disorders , 1996 , pp. 85s - 89s
Copyright
Copyright © Elsevier, Paris 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Achte, KAOn prognosis and rehabilitation in schizophrenic and paranoid psychoses. Acta Psychiatr Scand 1967; 196: 1–217Google ScholarPubMed
Beck, MNTwenty-five and thirty-five year follow-up of first admissions to mental hospital. Can J Psychiatry 1968; 13: 219–29Google ScholarPubMed
Bland, RCParker, HOrn, HPrognosis in schizophrenia. Arch Cen Psychiatry 1973; 33: 949–54CrossRefGoogle Scholar
Boyer, PAmisulpride in the treatment of negative schizophrenic symptoms: results of a double-blind controlled trial versus a placebo. In: Borenstein, , et al. Amisulpride. Paris: Expansion Scientifique Française, 1989; 111–23Google Scholar
Carpenter, WTHeinrichs, REAlphs, LDTreatment of negative symptoms. Schizophr Bull 1985; 11: 453–6CrossRefGoogle ScholarPubMed
Chouinard, GArnott, WClinical review of risperidone. Can J Psychiatry 1993;38suppl 3:589–95Google ScholarPubMed
Clerc, GÉtude en double-insu de l’amisulpride (Solian® 50) à différentes posologies chez des malades schizophrènes déficitaires. Sem Hop Paris 1989;65(17):1079–82Google Scholar
Davis, JAndriukatis, SThe natural cause of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacol 1986; 6: 25–105CrossRefGoogle Scholar
Delay, JDeniker, PMéthodes chimiothérapiques en psychiatrie. Paris: Masson, 1961Google Scholar
Deniker, PGinestet, DNeuroleptiquesEncycl Med-Chir Psychiatrie. Paris: Elsevier, 1973; 37860 b 20Google Scholar
Dollfus, SPetit, MEssai d’évaluation de l’efficacité des neuroleptiques sur le devenir des schizophrènes. Encéphale 1991; 17: 247–53Google Scholar
Dollfus, SPetit, MLesieur, P, et al. Principal-component analysis of PANSS and SANS-SAPS global rating in schizophrenic patientsEur Psychiatry 1991;6:251–9Google Scholar
Ey, HNeuroleptiques et services psychiatriques hospitaliers. Confrontations Psychiatriques 1975; 13: 19–59Google Scholar
Hasting, DWFollow-up results in psychiatric illness. Am J Psychiatry 1958; 114: 1057–66CrossRefGoogle Scholar
Imlach, NWMurphy, KPThe outcome of years continuous treatment with fluphenazine decanoate. In: Schiff, AARoth, MFreeman, HL eds. Schizophrenia: new pharmacological and clinical developments. Royal Society of Medecine services international congress and symposium, series 94 1985; 35–45Google Scholar
Kane, JMHonigfeld, GSinger, JMeitzer, HClozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96CrossRefGoogle ScholarPubMed
Langfeldt, GSchizophrenia: diagnosis and prognosis. Behav Sci 1969; 14: 173–82CrossRefGoogle ScholarPubMed
Liberman, RPsychiatric rehabilitation of chronic mental patients Washington: American Psychiatric Press, 1989Google Scholar
Meltzer, HYBurnett, SBastani, BRamirez, LFEffects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Comm Psychiatry 1990; 41: 892–7Google ScholarPubMed
Meltzer, HYNew drugs for the treatment of schizophrenia. Psychiatr Clin North America 1993; 16: 365–85CrossRefGoogle ScholarPubMed
Möller, HJvon Zerssen, DWerner-Eller, KWüschner-Stockhelm, MOutcome in schizophrenia and similar paranoid psychoses. Schizophr Bull 1982; 8: 99–108CrossRefGoogle ScholarPubMed
Pere, JJChaumet-Riffaud, PDBourdeix, IBourdain, MLa Clozapine en France. Encéphale 1992; 18: 427–32Google Scholar
Peron-Magnan, PChimiothérapie et évolution des schizophrénies. Confrontations Psychiatriques 1968; 2: 125–37Google Scholar
Pichot, PBoyer, PÉtude multicentrique contrôlée, en double insu, amisulpride (Solian® 50) contre fluphénazine à faibles doses dans le traitement du syndrome déficitaire des schizophrénies chroniques. Ann Psychiatr 1988;3(3bis):312–20Google Scholar
Prudo, RBlum, MFive-year outcome and prognosis in schizophrenia. Br J Psychiatry 1987; 150: 345–54CrossRefGoogle Scholar
Reine, GLlorca, PMIstria, NBougerol, THScotto, ICExpérience clinique d’utilisation de la clozapine. Psychologie Médicale 1992; 24: 1583–95Google Scholar
Rennie, TACFollow-up study of five hundred patients with schizophrenia admitted to the hospital from 1913 to 1923. Arch Neurol Psychiatry 1939; 42: 877–91CrossRefGoogle Scholar
Revicki, DALuce, BRWeschler, JMBrown, REAdler, MACost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Comm Psychiatry 1990; 41: 850–4Google ScholarPubMed
Rupp, CFletcher, EKA five to ten year follow-up study of 641 schizophrenic cases. Am J Psychiatry 1940; 96: 877–88CrossRefGoogle Scholar
Souêtre, EMartin, PLecanu, JPÉvaluation médico-économique des neuroleptiques dans la schizophrénie. Amisulpride versus halopéridol. Encéphale 1992; 18: 263–9Google Scholar
Stakler, HThe prognosis in schizophrenia. Based on a follow-up study of 129 cases treated by ordinary methods. J Ment Sci 1939; 85: 1224–40Google Scholar
Watt, DCKatz, CShepherd, MThe natural history of schizophrenia: a 5 year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med 1983; 13: 663–70CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.